621 related articles for article (PubMed ID: 33426614)
1. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.
Ha DK; Kim MJ; Han N; Kwak JH; Baek IH
Clin Drug Investig; 2021 Feb; 41(2):119-132. PubMed ID: 33426614
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B
Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis.
Lee S; Staatz CE; Han N; Baek IH
Eur J Clin Pharmacol; 2022 Sep; 78(9):1365-1376. PubMed ID: 35729340
[TBL] [Abstract][Full Text] [Related]
5. Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review.
DeFalco AP; Lazim R; Cope NE
Ann Pharmacother; 2021 May; 55(5):650-657. PubMed ID: 32909437
[TBL] [Abstract][Full Text] [Related]
6. Ubrogepant for the treatment of migraine.
Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
[TBL] [Abstract][Full Text] [Related]
7. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
9. Ubrogepant to treat migraine.
Dhir A
Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
[TBL] [Abstract][Full Text] [Related]
10. Ubrogepant for the Treatment of Migraine.
Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
[TBL] [Abstract][Full Text] [Related]
11. Targeting CGRP and 5-HT
Moreno-Ajona D; Chan C; Villar-Martínez MD; Goadsby PJ
Headache; 2019 Jul; 59 Suppl 2():3-19. PubMed ID: 31291016
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
[TBL] [Abstract][Full Text] [Related]
14. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
Nedd M; Garland S; Falk N; Wilk A
Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis.
Hong P; Liu Y
Int J Neurosci; 2017 Jan; 127(1):20-27. PubMed ID: 26728923
[TBL] [Abstract][Full Text] [Related]
16. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
Voss T; Lipton RB; Dodick DW; Dupre N; Ge JY; Bachman R; Assaid C; Aurora SK; Michelson D
Cephalalgia; 2016 Aug; 36(9):887-98. PubMed ID: 27269043
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Calcitonin Gene-Related Peptide Receptor Antagonists for Migraine Treatment: A Meta-Analysis.
Pak K; Kim J; Lee GH; Cho JW; Kim HW
Eur Neurol; 2022; 85(3):195-201. PubMed ID: 35100579
[TBL] [Abstract][Full Text] [Related]
18. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP; Liang CS; Chang CM; Yang CC; Shih PH; Yau YC; Tang KT; Wang SJ
JAMA Netw Open; 2021 Oct; 4(10):e2128544. PubMed ID: 34633423
[TBL] [Abstract][Full Text] [Related]
19. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
20. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
